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scientiﬁc literature was searched for systematic reviews and
meta-analyses of effectiveness and efﬁcacy data, as well as for
health economic evaluations. IMPLEMENTATION STRAT-
EGY: All currently reimbursed drugs with ATC-codes R03 and
R05 were included in the review. A project team consisting of a
pharmacist, a health economist and a legal advisor led the inves-
tigation. 3 external clinical experts were also attached to the
project group. These experts were recruited based on nomina-
tions from stakeholders, both from the health care system and
patient organizations. Companies marketing a product included
in a review were asked to submit documentation about which
studies best support the effectiveness and cost-effectiveness of
their product. Before the report was published it was sent out for
review by the stakeholders involved. RESULTS: A number of
systematic reviews of a good quality were identiﬁed and were
found to be relevant for the decision situation in Sweden. The
quality of the evidence available to support the different types of
inhaled medicines varied widely. Inhaled steroids, long action
beta-agonists and combinations thereof have a large number of
studies. The short acting beta agonists do not have as much
evidence and the trials available are often small. There is also a
shortage of head to head trials of relevant products at relevant
doses. In this ﬁeld there is also the added complication of differ-
ent inhaler devices in addition to the different active substances.
The value of having a wider range of substances and inhaler
devices has not been studied and quantiﬁed. Based on the avail-
able evidence the products were compared at equivalent doses.
Based on this comparison one product was considered too expen-
sive compared to the alternatives and recommendations were
made on which drugs should primarily be considered for new
patients. The preferred measure of effect in health economic
evaluations the QALY was rarely used within this ﬁeld.
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ORGANIZATION: The Pharmaceutical Beneﬁts Board in
Sweden (LFN) PROBLEM OR ISSUE ADDRESSED: In Sweden,
the Pharmaceutical Beneﬁts Board (LFN) was instituted in 2002
with the purpose of contributing to a rational and cost-effective
use of pharmaceuticals. The Board’s assignment is to systemati-
cally and in accordance with national prioritization guidelines
decide which pharmaceuticals should be reimbursed. Societal
cost-effectiveness is a key decision parameter. One task of the
LFN is to review the subsidy status of all products (~3 000
products) that were already in the pharmaceutical beneﬁts when
the Board was instituted. All the drugs used for treating asthma,
COPD and coughs (43 products in total)were assessed to see
whether they still merited reimbursement. GOALS: The primary
purpose of the review of these products is to inform the Board’s
decisions on subsidy status for the pharmaceuticals used within
the therapeutic area of asthma, COPD and coughs. The second-
ary purpose is to help other decision makers in Swedish health
care to rationally and cost-effectively use pharmaceuticals in the
treatment of these diseases. OUTCOMES ITEMS USED IN
THE DECISION: The scientiﬁc literature was searched for sys-
tematic reviews and meta-analyses of effectiveness and efﬁcacy
data, evidence on the humanistic burden of disease, as well as for
health economic evaluations. IMPLEMENTATION STRAT-
EGY: All currently reimbursed drugs with ATC-codes R03 and
R05 were included in the review. A project team consisting of a
pharmacist, a health economist and a legal advisor led the inves-
tigation. 3 external clinical experts were also attached to the
project group. These experts were recruited based on nomina-
tions from stakeholders, both from the health care system and
patient organizations. Companies marketing a product included
in a review were asked to submit documentation about which
studies best support the effectiveness and cost-effectiveness of
their product. Before the report was published it was sent out for
review by the stakeholders involved. RESULTS: Of the 43 prod-
ucts reviewed, 34 retained their reimbursement status. Eight
products were removed from reimbursement while limited reim-
bursement was granted for one medicine. Of these nine medi-
cines, ﬁve are cough medicines and four are medicines against
asthma and/or COPD. The four asthma/COPD products were
removed primarily because they were not judged to be cost-
effective. The medicines against cough were removed from
reimbursement due to the severity of the disease being low.
CASE4
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ORGANIZATION: Authors: S, B, Freedman (MD). S, Deiratany
(MD), S, Bensler (MD), R Goldman (MD) (The Department of
Paediatrics, Division of Paediatric Emergency Medicine (S.B.F.,
S.D.) and the Division of Rheumatology (S.B.) The Hospital for
Sick Children, The University of Toronto, Toronto, ON, Canada
and the Division of Pediatric Emergency Medicine (R.D.G.), BC
Children’s Hospital and the Child & Family Research Institute
(CFRI), Department of Pediatrics, University of British Colum-
bia, British Columbia. GOALS: Title: Development and Valida-
tion of a Caregiver Gastroenteritis Knowledge Questionnaire.
OUTCOMES ITEMS USED IN THE DECISION: Background:
Gastroenteritis remains a leading cause of childhood morbidity
and mortality and results in many non-urgent emergency depart-
ment (ED) visits due to caregiver knowledge deﬁciencies. Chil-
dren of caregivers who are less knowledgeable are at increased
risk of presenting to a hospital secondary to dehydration.
IMPLEMENTATION STRATEGY: Purpose: The primary aim
of this study was to describe the reliability and validity of a
Caregiver Gastroenteritis Knowledge Questionnaire (CGKQ).
METHODS: The CGKQ design incorporated 38 true/false ques-
tions covering signs of dehydration, indications to see a physi-
cian, oral re-hydration therapy, solid intake and re-feeding,
medication use and disease transmission. Following validation
procedures, 80 caregivers, 25 nurses and 18 pediatric emergency
medicine physicians and 4 general pediatricians completed the
questionnaire. One month later all participants completed the
questionnaire a second time. RESULTS: Findings: Content valid-
ity was conﬁrmed qualitatively. Construct validity was demon-
strated by incremental increases (P < 0.001) in mean total scores
from caregivers to nurses to physicians at both time points. A
wide range of scores were recorded, from 12 to 38. Multiple
regression analysis revealed the number of prior visits for gastro-
enteritis was inversely associated with overall caregiver score
(P = 0.02). Internal test-retest data gave a single measure intrac-
lass correlation coefﬁcient of 0.74 (95% CI: 0.62, 0.83) and
domain coefﬁcients >0.50 for all domains except for signs of
dehydration. The Pearson correlation coefﬁcient for the test-
retest score was 0.75. Internal consistency was demonstrated
with a Cronbach’s alpha of 0.67 at time 0 and 0.80 at time 1
month. LESSONS LEARNED: The CGKQ is a reliable, valid
tool suitable for identifying knowledge gaps amongst caregivers
and measuring improvement following educational intervention.
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